Pharmacogenomic tests for cardiovascular diseases: Innovation for the health care system
In 2010, 80,000 Canadians died from cardiovascular diseases (CVD), which represents 35 percent of all deaths in the country. At the moment, 1.3 million Canadians suffer from CVD, with associated costs reaching $22.2 billion a year – the highest proportion for the Canadian health care system.
The goal of this project is to develop pharmacogenomic tests that would render more effective the management of patients with CVD. These decision-support tools developed for health managers would present many benefits:
- Improved treatments, with reduced negative effects
- Greater patient confidence in the treatment and in turn better compliance
- Reduced costs to the Canadian health care system
- Better market access for cardiovascular drugs and diagnostic tests
These tests will have an immediate, lasting impact on the economic front and in clinical practice, both here and around the world.
Co-applicant – End-user:
| Rob | Hegele | London Regional Genomics |